Stealth Peptides Inc. Announces Clinical Phase I Results With Bendavia™ Demonstrating Safety And Tolerability With Highly Predictable Pharmacokinetics

BOSTON–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today the results of its first–in–humans Phase I clinical trial of BendaviaTM, a new chemical entity that targets mitochondria to treat ischemia reperfusion injury. This double–blind, placebo–controlled, randomized study evaluated healthy male and female volunteers representing a broad range of adult [...]

read more

On September 28th, 2010, posted in: Press Releases by admin